Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update

Ahmed, Muneeb; Solbiati, Luigi; Brace, Christopher L.; Breen, David J.; Callstrom, Matthew R.; Charboneau, J. William; Chen, Minhua; Choi, Byung Ihn; Baère, Thierry De; Dodd, Gerald D.; Dupuy, Damian E.; Gervais, Debra A.; Gianfelice, David; Gillams, Alice; Lee, Fred T.; Leen, Edward; Lencioni, Riccardo; Littrup, Peter J.; Livraghi, Tito; Lu, David; McGahan, John P.; Meloni, Maria Franca; Nikolic, Boris; Pereira, Philippe L.; Liang, Ping; Rhim, Hyunchul; Rose, Steven C.; Salem, Riad; Sofocleous, Constantinos T.; Solomon, Stephen B.; Soulen, Michael C.; Tanaka, Masatoshi; Vogl, Thomas J.; Wood, Bradford J.; Goldberg, S. Nahum

doi:10.1148/radiol.14132958

Cited by 899 publications

(524 citation statements)

References 99 publications

Supporting

Mentioning

515

Contrasting

Unclassified

Order By: Relevance

“…Tumors not technically amenable to radiofrequency ablation (RFA) were treated with either percutaneous ethanol injection (PEI) or irreversible electroporation (IRE). Technique for ablation was according to standard practice guidelines [8], using either a percutaneous or surgical approach. RFA was performed using either a single probe (Cool-tip, Covidien, Mansfield, MA) or a multi-pronged probe (StarBurst Talon, Angiodynamics, Latham, NY).…”

Section: Methodsmentioning

confidence: 99%

Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts

Padia

Chewning

Kogut

et al. 2014

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose Locoregional therapy for hepatocellular carcinoma (HCC) can be challenging in patients with a transjugular intrahepatic portosystemic shunt (TIPS). This study compares safety and imaging response of ablation, chemoembolization, radioembolization, and supportive care in patients with both TIPS and HCC. Methods This retrospective study included 48 patients who had both a TIPS and a diagnosis of HCC. Twenty-nine of 48 (60 %) underwent treatment for HCC, and 19/48 (40 %) received best supportive care (i.e., symptomatic management only). While etiology of cirrhosis and indication for TIPS were similar between the two groups, treated patients had better baseline liver function (34 vs. 67 % Child-Pugh class C). Tumor characteristics were similar between the two groups. A total of 39 ablations, 17 chemoembolizations, and 10 yttrium-90 radioembolizations were performed on 29 patients.Results Ablation procedures resulted in low rates of hepatotoxicity and clinical toxicity. Post-embolization/ ablation syndrome occurred more frequently in patients undergoing chemoembolization than ablation (47 vs. 15 %). Significant hepatic dysfunction occurred more frequently in the chemoembolization group than the ablation group. Follow-up imaging response showed objective response in 100 % of ablation procedures, 67 % of radioembolization procedures, and 50 % of chemoembolization procedures (p = 0.001). When censored for OLT, patients undergoing treatment survived longer than patients receiving supportive care (2273 v. 439 days, p = 0.001). Conclusions Ablation appears to be safe and efficacious for HCC in patients with TIPS. Catheter-based approaches are associated with potential increased toxicity in this patient population. Chemoembolization appears to be associated with increased toxicity compared to radioembolization.

show abstract

Section: Methodsmentioning

confidence: 99%

Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts

Padia

Chewning

Kogut

et al. 2014

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

“…Since the early 1980s, local therapies have emerged for the treatment of non-resectable hepatic tumors [4]. Tumor ablation is defined as a direct application of non-energy (chemical) or energybased (thermal and non-thermal) modalities via applicator (probes, electrodes and antennae) that eradicate or destroy a tumor either through thermal (heat or cold) or non-thermal mechanisms [4].…”

Section: Background and Definitionmentioning

confidence: 99%

“…Tumor ablation is defined as a direct application of non-energy (chemical) or energybased (thermal and non-thermal) modalities via applicator (probes, electrodes and antennae) that eradicate or destroy a tumor either through thermal (heat or cold) or non-thermal mechanisms [4]. Currently the most established thermal ablative techniques are RFA, MWA, LITT and cryotherapy (▶ Table 1 -3).…”

Section: Background and Definitionmentioning

confidence: 99%

“…Thus the term "microwave ablation" should replace the less succinct terms "percutaneous microwave coagulation therapy" and "microwave coagulation therapy" [4,7]. In recent years, numerous different devices and generators with higher energies have been developed for MWA in order to increase the size of ablation zones, to achieve larger ablation margins and to decrease local tumor progression.…”

Section: Background and Definitionmentioning

confidence: 99%

“…The antenna which is used in MWA is often referred to as a "needle" or other nonspecific terms, but generally the terms "applicator", "antenna" and "probe" should be used for energy-based devices [4].…”

Section: Direct Comparison Of Mwa and Rfamentioning

confidence: 99%

See 2 more Smart Citations

Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms – Review Article

Vogl

Nour-Eldin

Hammerstingl

et al. 2017

Fortschr Röntgenstr

126

View full text Add to dashboard Cite

ZUSAMMENFASSUNGHintergrund Der lokoregionale interventionelle onkologische Behandlungsansatz ist eine anerkannte Behandlungsoption bei Lebermalignomen, insbesondere beim hepatozellulären Karzinom (HCC) und oligonodulären Lebermetastasen. Material und Methode ABSTR AC T PurposeThe locoregional interventional oncological treatment approach is an accepted modality for liver neoplasms, especially for hepatocellular carcinoma (HCC) and oligonodular liver metastases. Materials and MethodsThe main aim of ablation therapies like microwave ablation (MWA) is to eradicate all malignant cells in a minimally invasive technique under imaging guidance while preserving the healthy tissue with a sufficient safety margin (at least 5 mm) surrounding the ablated lesion.Results Ablation therapy can be performed via a percutaneous, laparoscopic or intraoperative approach under ultrasound, MRI or CT guidance for adequate localization and monitoring of the ablation process.Conclusion Ablation is the method of choice for oligonodular HCCs ≤ 3 cm. The technical success rate varies from 88 % to This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.98 % and progression-free survival (PFS) at 3 years from 27 % to 91.7 %. The same criteria apply to the therapy of liver metastases. Key Points▪ Careful selection of patients proves to be essential for optimum results of MWA ▪ Interventionists should be familiar with all aspects of complication and rapid assessment of imaging methods in order to evaluate induced damage by thermal ablation ▪ MWA seems to have some advantages over radiofrequency ablation, like shorter ablation time, less pain, less heat sink effect; however, scientific proof is needed

show abstract

Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Repeat hepatectomy and percutaneous radiofrequency ablation (PRFA) are most commonly used to treat early-stage recurrent hepatocellular carcinoma (RHCC) after initial resection, but previous studies comparing the effectiveness of the 2 treatments have reported conflicting results.OBJECTIVE To compare the long-term survival outcomes after repeat hepatectomy with those after PRFA among patients with early-stage RHCC. DESIGN, SETTING, AND PARTICIPANTSThis open-label randomized clinical trial was conducted at the Eastern Hepatobiliary Surgery Hospital and the National Center for Liver Cancer of China. A total of 240 patients with RHCC (with a solitary nodule diameter of Յ5 cm; 3 or fewer nodules, each Յ3 cm in diameter; and no macroscopic vascular invasion or distant metastasis) were randomized 1:1 to receive repeat hepatectomy or PRFA between

show abstract

Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update

Abstract: ablation in comparison with other available treatments (97,98).

Cited by 899 publications

References 99 publications

Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts

Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts

Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms – Review Article

Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma

Contact Info

Product

Resources

About